Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

We report a Phase I/II clinical trial of poly-(styrene-co-maleyl-half-n-butylate)-neocarzinostatin (SMANCS) for intra-arterial treatment of hepatoma. Early patients received 4 or 8 mg SMANCS dissolved in Lipiodol; later patients were treated according to tumour size and degree of filling achieved. SMANCS/Lipiodol drained rapidly from normal liver but was retained within tumour interstitium. Tumour nodules filled with SMANCS/Lipiodol usually stabilised and often regressed. No UICC criteria-defined responses were achieved, partly due to difficulties of filling several lesions simultaneously. Signs of therapeutic activity suggest a more extensive clinical study is warranted.

Original publication




Journal article


Int J Oncol

Publication Date





1217 - 1223


Abdominal Pain, Adult, Aged, Antineoplastic Agents, Carcinoma, Hepatocellular, Drug Evaluation, Drug Hypersensitivity, Female, Fever, Humans, Hypotension, Injections, Intra-Arterial, Liver, Liver Neoplasms, Male, Maleic Anhydrides, Middle Aged, Polystyrenes, Radiography, Syncope, Treatment Outcome, Zinostatin, alpha-Fetoproteins